According to a research report "Plasma Fractionation Market published by MarketsandMarkets, the global plasma fractionation market is expected to reach USD 36.7 billion by 2027, with a projected compound annual growth rate (CAGR) of 6.7% from 2022 to 2027. The report highlights several factors contributing to the market's growth:
- Growing Use of Immunoglobulins: The increasing utilization of immunoglobulins in various off-label indications is driving the demand for plasma fractionation products. Immunoglobulins are used in the treatment of immunodeficiency disorders, autoimmune diseases, and neurological disorders, among others. This expanded application of immunoglobulins is propelling market growth.
- Genetic Research and Diagnosing Immunodeficiency: Genetic research for characterizing and diagnosing immunodeficiency disorders is fueling the application of plasma fractionation products. As genetic understanding improves, the demand for plasma-derived products for diagnosing and managing these conditions is expected to increase.
- Growing Geriatric Population: The global population of individuals aged 60 and above is projected to reach 2.1 billion by 2050. The elderly population is more susceptible to various diseases, including immune deficiencies and neurological disorders, which require plasma-derived products for treatment. This demographic trend is contributing to the growth of the plasma fractionation market.
- Increased Use of Protease Inhibitors: Protease inhibitors, such as alpha-1-antitrypsin, are increasingly being used for the treatment of lung diseases. The rising incidence of respiratory disorders, coupled with the therapeutic benefits of protease inhibitors, is driving the demand for plasma fractionation products in this segment.
- Increased Incidence of Communicable Diseases: The prevalence of communicable diseases, including viral infections, has been rising globally. Plasma fractionation plays a vital role in producing essential therapies, such as immunoglobulins, for the prevention and treatment of these diseases. The increasing incidence of communicable diseases is fueling the demand for plasma fractionation products.
Download Report Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284
The report also mentions that clinical research organizations, hospitals, and clinics are the key end-users of plasma fractionation products. These institutions require plasma-derived products for various research studies, clinical trials, and patient treatments.
Key Market Player:
The global plasma fractionation market is highly consolidated. The prominent players operating in this market include CSL (Australia), Grifols, S.A. (Spain), Shire (US), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), Biotest AG (Germany), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Bio Products Ltd. (UK), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India), SK Plasma (Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), KabaFusion (US), Centurion Pharma (Istanbul), ADMA Biologics, Inc. (US), PlasmaGen BioSciences Pvt. Ltd. (India), Virchow Biotech Private Limited (India), Fusion Healthcare (India), and Hemarus Therapeutics Limited (India). Geographic expansions and collaborations are the key growth strategies undertaken by these companies to maintain their positions in the market.
Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=93798284
In 2021, the IVIG (intravenous immunoglobulin) segment accounted for the largest share of the Immunoglobulins market within the plasma fractionation industry. This segment's significant market share can be attributed to its widespread use in various disease indications, both on-label and off-label. IVIG is utilized for conditions such as dermatomyositis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), immune cytopenias, hypogammaglobulinemia, primary antibody deficiency, vacuities, multiple sclerosis, asthma, systemic lupus erythematosus, and other ailments. The shorter response period of IVIG compared to steroids or oral immunosuppressants, increasing healthcare investments, and the growing number of patients with autoimmune diseases and other pathological conditions are key factors contributing to the growth of this market segment.
On the other hand, the pulmonology segment is expected to exhibit the highest compound annual growth rate (CAGR) during the forecast period. This segment focuses on applications related to lung diseases and respiratory disorders. The significant growth in the pulmonology segment is primarily driven by the increased use of protease inhibitors, particularly alpha-1-antitrypsin, in recent years. As the global geriatric population continues to rise, the prevalence of conditions like alpha-1-antitrypsin deficiency (AATD) and chronic obstructive pulmonary disease (COPD) is also expected to increase. This, in turn, is anticipated to drive the demand for plasma-derived alpha-1-antitrypsin in the coming years, making the pulmonology segment the fastest-growing during the forecast period.
North America was the largest regional market for plasma fractionation market in 2021
The global plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the innovations in manufacturing processes such as presence of advanced virus removal technologies (such as nanofiltration), and the development of newer plasma products such as ceruloplasmin and IgA, high number of registered hemophilic patients and largest number of plasma collection center. However, the market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growth in increasing number of hemophilic patients, as well as factors such as the increasing number of organ transplantations, modified regulations and monitoring of the implementation of procedures, policies, and guidelines to promote innovation and commercialization, increasing awareness about technologically advanced products in the region, and the improving standard of living across several APAC countries.
Report Link: Plasma Fractionation Market
Recent Development:
- Baxter International Inc. acquired ChemoSera S.A. in 2022. The acquisition will expand Baxter’s portfolio of plasma fractionation products and enable the company to expand its presence in the European markets.
- Biovian Oy acquired ViroClinics Biosciences B.V. in 2022. The acquisition will expand Biovian’s plasma fractionation capabilities, increase its global presence, and enable the company to enhance its offerings in the field of plasma-derived biopharmaceuticals.
- Takeda Pharmaceutical Company Limited acquired Shire Plc in 2022. This acquisition will broaden Takeda’s product portfolio, enabling the company to expand its presence in the plasma fractionation market.
- Grifols S.A. acquired Hologic Inc. in 2022. The acquisition of Hologic’s business will enable Grifols to expand its offering of plasma fractionation products and services, as well as its global presence.
- CSL Limited acquired Terumo BCT in 2023. This acquisition will enable CSL to expand its product portfolio and strengthen its position in the global plasma fractionation market.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
About MarketsandMarkets™
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are moulded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit MarketsandMarkets™ or follow us on Twitter, LinkedIn and Facebook.
